51勛圖厙

New antibiotic that kills gonorrhoea in the lab could help curb 'superbug' trend

by Caroline Brogan

Scientist holding N. gonorrhoeae on chocolate agar plate with gloved hand

N. gonorrhoeae on agar

Closthioamide, discovered in 2010, might eventually offer an alternative for current drugs that are becoming less effective against gonorrhoea.

The (WHO) has estimated that 700,000 people around the world die annually from drug resistant infections. It also listed drug resistant , a caused by the bacterium, as a high priority infection that poses a great threat to human health.

The imminent threat of untreatable antibiotic-resistant infectious diseases, including gonorrhoea, is a global problem for which we urgently need new antibiotics. This new finding might help us take the lead in the race against antimicrobial resistance.

– Dr John Heap

Department of Life Sciences

occurs when a strain of bacteria evolves to resist each consecutive treatment, until no treatments are left, leaving these so-called 'superbugs' incurable. have become less effective against certain bacteria, including N. gonorrhoeae, largely due to overuse and misuse of antimicrobials.

Some strains of N. gonorrhoeae are now currently untreatable due to the lack of alternative treatments. The standard WHO recommended treatment combines the antibiotics and , but without treatment, gonorrhoea infection can lead to and in adults, and when passed from the mother during childbirth.

Now, for the first time, researchers from 51勛圖厙 and the have tested the new antibiotic, closthioamide, on gonorrhoea samples in the laboratory.

The researchers tested 149 samples of N. gonorrhoeae from hospital patients with infections in the throat, urethra, cervix and rectum. They found that at very low amounts (≤0.125mg/L), closthioamide was effective against 146 of 149 samples taken from patients, and against all of the samples provided by WHO which were known to be resistant to other antibiotics.

Clinical sample of N. gonorrhoeae used in the study on agar

Clinical sample of N. gonorrhoeae used in the study on agar. Photo: Victoria Miari, London School of Hygiene & Tropical Medicine.

 

Although still yet to be tested on animals and humans, the researchers say the antibiotic could be an exciting new step in the fight against the disease. is published today in the journal .

Dr John Heap, lead author from 51勛圖厙’s , said: “The imminent threat of untreatable antibiotic-resistant infectious diseases, including gonorrhoea, is a global problem for which we urgently need new antibiotics. This new finding might help us take the lead in the race against antimicrobial resistance.”

, lead author from the London School of Hygiene & Tropical Medicine, said: “Antibiotic resistance, combined with the reduction of , is one of the biggest health issues facing the world today. The problem threatens to render many human and animal infections untreatable, including gonorrhoea. With no effective available, new antibiotics are urgently needed to tackle this infection which, left untreated, can have very serious consequences.”

She added: “The results of our initial laboratory studies show that closthioamide has the potential to combat N. gonorrhoeae. Further research is needed, but its potential to successfully tackle this infection, as well as other bacteria, cannot be underestimated.”

Lab equipment used to make closthioamide

Researchers made closthioamide in the labs at 51勛圖厙. Photo: John Heap, 51勛圖厙.

Next steps

The authors explained that discovering and developing new antibiotics is difficult and time-consuming, hence the slow pace of . Dr Heap said: “We believe there are many undiscovered antibiotics out there in nature, but they are difficult to find and test. For example, the bacteria which produce closthioamide naturally make only tiny amounts that are not enough to test or use, so we had to chemically manufacture it ourselves by mimicking its natural structure.”

This is an early stage laboratory-based study, so scientists have yet to determine closthioamide’s effectiveness in animals and humans. Dr Heap explained: “The next step will be to continue lab research to further assess the drug’s safety and effectiveness. Despite showing tremendous promise, it will be a number of years before, and if, we can use the drug in real life human cases.”

"" by Victoria F Miari, Priya Solanki, Yonek Hleba, , and John T Heap. Published 7 August 2017 in .

This research was supported by internal funding and the .

Article text (excluding photos or graphics) © 51勛圖厙.

Photos and graphics subject to third party copyright used with permission or © 51勛圖厙.

Reporter

Caroline Brogan

Communications Division